KR20160063695A - A method to treat type ii diabetes mellitus by applying extracorporeal shockwave to a subject - Google Patents
A method to treat type ii diabetes mellitus by applying extracorporeal shockwave to a subject Download PDFInfo
- Publication number
- KR20160063695A KR20160063695A KR1020140167276A KR20140167276A KR20160063695A KR 20160063695 A KR20160063695 A KR 20160063695A KR 1020140167276 A KR1020140167276 A KR 1020140167276A KR 20140167276 A KR20140167276 A KR 20140167276A KR 20160063695 A KR20160063695 A KR 20160063695A
- Authority
- KR
- South Korea
- Prior art keywords
- shock wave
- subject
- extracorporeal shock
- diabetes mellitus
- type
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
- Y10S977/929—Ultrasound contrast agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Otolaryngology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
The present invention relates to a method for preventing or treating type 2 diabetes by applying an extracorporeal shock wave to a subject.
Diabetes mellitus is a type of metabolic disease that lacks insulin secretion or does not function normally. It is characterized by hyperglycemia in which the concentration of glucose in the blood increases. Hyperglycemia causes various symptoms and signs, and glucose is released from the urine .
Diabetes is divided into type 1 and type 2, type 1 diabetes occurs because insulin can not be produced, type 2 diabetes occurs when insulin is secreted but the cells have insulin resistance . It is also known as non-insulin dependent diabetes mellitus because it is not abnormal in insulin secretion in type 2 diabetes. Type 2 diabetes mellitus is often associated with obesity due to high calorie, high protein diet and lack of exercise. It can also be caused by genetic factors, infection, certain medications, and pancreatic surgery.
Currently, treatment for type 2 diabetes is the best way to reduce weight through lifestyle modification, such as changing the diet and exercising. In some cases, a drug such as an insulin sensitizer is administered. However, to date, there has not been developed a therapeutic or therapeutic method that can directly treat type 2 diabetes.
It is an object of the present invention to provide a method for preventing or treating type 2 diabetes by applying an extracorporeal shock wave to a subject.
In order to solve the above problems,
The present invention provides a method for preventing or treating type 2 diabetes by applying a therapeutically effective amount of extracorporeal shock wave to a subject in need of treatment.
In the present invention, "type 2 diabetes" means non-insulin dependent diabetes caused by insulin resistance.
In the present invention, the term " subject to be treated "means a mammal such as a human, such as a human, a mouse, a hamster, a rat, a pellet, a guinea pig, a rabbit, a dog, a primate, a pig, It can be human.
The term " therapeutically effective degree "in the present invention means the degree to which a biological or medical response is induced in an animal or human being considered by a researcher, veterinarian, physician or other clinician, And the extent to which mitigation is induced. It is apparent to those skilled in the art that the application degree (intensity and frequency) of the extracorporeal shock wave of the present invention will vary depending on the state of the object and the desired effect.
Extracorporeal Shock Wave is a longitudinal sound wave propagating through water or soft tissue like an ultrasonic wave. Unlike ultrasound, the shockwave is a single pressure pulse with a short needle-like positive spike in very short time (<1 μs) followed by a tensile phase and has an amplitude of up to 100 MPa.
In the present invention, the extracorporeal shock wave can be a low-energy extracorporeal shock pile. Preferably, the external shock wave is 0.056 mJ / mm < 2 > The following low-energy impact shock files can be. However, the energy intensity is not limited thereto.
In the present invention, "application" means that an extracorporeal shock wave is irradiated to a target object. In the present invention, the extracorporeal shock wave may be applied to a region covering the abdomen of the subject. However, the portion where the extracorporeal shock wave can be irradiated is not limited thereto.
The present invention provides the use of extracorporeal shock wave for the prevention or treatment of type 2 diabetes.
In the present invention, extracorporeal shock wave application may be performed in combination with one or more drugs or treatments. For example, an insulin resistance improving agent or an antihypertensive agent may be administered together with the application of the extracorporeal shock wave of the present invention. However, the types of drugs or treatments that can be used in combination with the present invention are not limited thereto.
The method of the present invention can effectively prevent and treat type 2 diabetes by improving insulin resistance, which is the root cause of type 2 diabetes.
FIG. 1 shows glucose intolerance in a glucose tolerance test in animal model mice to which extracorporeal shock waves were applied.
FIG. 2 is a graph showing that insulin resistance was reduced in an insulin tolerance test in an animal model mouse to which extracorporeal shock waves were applied.
FIG. 3 is a graph showing that the extracorporeal shock wave irradiation reduces the inflammatory findings of adipose tissue.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples.
< Example 1> Effect of extracorporeal shock wave on insulin resistance
1-1. Preparation of animal model and investigation of extracorporeal shock wave
14, Issue 1, p91-103) by inducing high C57 / BL6 mice to induce insulin resistance by high fat diet for 15 weeks. (0.056mJ / mm2, 1000 impulses, every 3-4 days interval) during the 15-week high-fat dietary diet for the above 15 weeks. , And the extracorporeal shock wave was irradiated alternately.
1-2. Glucose tolerance test
The mouse prepared in 1-1 above was fasted and glucose 1 mg / g was injected intraperitoneally. After that, blood glucose level was measured at time intervals to track changes in glucose concentration.
The results are shown in Fig. In FIG. 1, it can be seen that the blood glucose level is lower at each measurement time in the shock wave application group (SW) than the control group (control). This implies that insulin resistance is improved by extracorporeal shock waves and glucose is metabolized.
1-3. Insulin resistance exam
The mouse prepared in 1-1 above was fasted and 1.0 U / kg insulin was injected intraperitoneally. After that, blood glucose level was measured at time intervals to measure changes in glucose concentration.
The results are shown in Fig. In FIG. 2, it can be seen that the blood glucose level is lower as time passes in the shock wave application group compared to the control group. This means that the insulin resistance is improved by the extracorporeal shock wave so that the blood glucose level is lowered more rapidly.
< Example 2> Effect of extracorporeal shock wave on adipose tissue inflammation
The mouse prepared in above 1-1 was euthanized and epididymal adipose tissue (visceral fat) was extracted, and hematoxylin and eosin were stained and then observed with a microscope.
2 in the control group and 2 in the extracorporeal shock wave application group are shown in FIG. 3 as representative drawings. FIG. 3 shows that leukocyte infiltration of adipose tissue was significantly reduced in the shock wave application group. This means that the inflammation of the adipose tissue, which is a factor for increasing the insulin resistance by the extracorporeal shock wave, is improved.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140167276A KR20160063695A (en) | 2014-11-27 | 2014-11-27 | A method to treat type ii diabetes mellitus by applying extracorporeal shockwave to a subject |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140167276A KR20160063695A (en) | 2014-11-27 | 2014-11-27 | A method to treat type ii diabetes mellitus by applying extracorporeal shockwave to a subject |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170107444A Division KR20170098788A (en) | 2017-08-24 | 2017-08-24 | A method to treat type Ⅱ diabetes mellitus by applying extracorporeal shockwave to a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160063695A true KR20160063695A (en) | 2016-06-07 |
Family
ID=56192804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140167276A KR20160063695A (en) | 2014-11-27 | 2014-11-27 | A method to treat type ii diabetes mellitus by applying extracorporeal shockwave to a subject |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160063695A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389372B2 (en) * | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
| US11389373B2 (en) * | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to prevent or treat opioid addiction |
| US11458069B2 (en) * | 2016-04-18 | 2022-10-04 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to treat medical conditions using reflexology zones |
-
2014
- 2014-11-27 KR KR1020140167276A patent/KR20160063695A/en active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11389372B2 (en) * | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
| US11389373B2 (en) * | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to prevent or treat opioid addiction |
| US11458069B2 (en) * | 2016-04-18 | 2022-10-04 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to treat medical conditions using reflexology zones |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Payne et al. | Bioelectric neuromodulation for gastrointestinal disorders: effectiveness and mechanisms | |
| Notarnicola et al. | The biological effects of extracorporeal shock wave therapy (eswt) on tendon tissue | |
| VILLÁNYI et al. | Short-term changes in renal function after extracorporeal shock wave lithotripsy in children | |
| Lee et al. | Dose-related effect of extracorporeal shock wave therapy for plantar fasciitis | |
| Andersson et al. | Low-level mechanical stimulation is sufficient to improve tendon healing in rats | |
| Armagan et al. | Effects of placebo-controlled continuous and pulsed ultrasound treatments on carpal tunnel syndrome: a randomized trial | |
| Handa et al. | Pretreatment with low‐energy shock waves induces renal vasoconstriction during standard shock wave lithotripsy (SWL): a treatment protocol known to reduce SWL‐induced renal injury | |
| Andersson et al. | Tissue memory in healing tendons: short loading episodes stimulate healing | |
| Montgomery et al. | Muscle and tendon heating rates with therapeutic ultrasound in horses | |
| KR20170098788A (en) | A method to treat type Ⅱ diabetes mellitus by applying extracorporeal shockwave to a subject | |
| Milligan et al. | The effect of lidocaine on postoperative jejunal motility in normal horses | |
| Maffulli et al. | New options in the management of tendinopathy | |
| Ilieva et al. | Radial shock wave therapy in patients with lateral epicondylitis | |
| KR20160063695A (en) | A method to treat type ii diabetes mellitus by applying extracorporeal shockwave to a subject | |
| Collins et al. | A clinical study of extracorporeal shock waves (ESW) for treatment of chronic lateral epicondylitis | |
| Cui et al. | Efficacy and safety of novel low-intensity pulsed ultrasound (LIPUS) in treating mild to moderate erectile dysfunction: a multicenter, randomized, double-blind, sham-controlled clinical study | |
| Yocom et al. | Review of the application and efficacy of extracorporeal shockwave therapy in equine tendon and ligament injuries | |
| Goel et al. | A comparative study between intralesional platelet rich plasma injection and extracorporeal shockwave therapy for the treatment of plantar fasciitis | |
| Wu et al. | Electrophysiological and functional effects of shock waves on the sciatic nerve of rats | |
| Margalef et al. | Percutaneous needle electrolysis reverses neurographic signs of nerve entrapment by induced fibrosis in mice | |
| Taherzadeh et al. | The Effect of 6 Weeks of Aerobic Exercise and Aqueous Extract of Caraway Seed on Expression of FNDC5 Gene and Serum Irisin Level in Obese Male Rats | |
| Narin et al. | Comparison of radial extracorporeal shock wave therapy in plantar fasciitis treatment using two different frequencies | |
| Li et al. | Sciatic nerve block combined with flurbiprofen inhibits spinal cord inflammation and improves postoperative pain in rats with plantar incision | |
| Grady et al. | Extracorporeal pulse-activated therapy versus injection: Treatment of recalcitrant plantar fasciitis | |
| Challis et al. | Cyclic pneumatic soft-tissue compression accelerates the union of distal radial osteotomies in an ovine model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| A107 | Divisional application of patent |